Ken Griffin’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $52.4M | Buy |
5,810,642
+4,288,072
| +282% | +$67.7M | 0.01% | 1316 |
|
|
2025
Q4 | $27.8M | Sell |
1,522,570
-596,592
| -28% | -$10.1M | ﹤0.01% | 1987 |
|
|
2025
Q3 | $31.1M | Buy |
+2,119,162
| New | +$36.3M | ﹤0.01% | 1840 |
|
|
2025
Q2 | – | Sell |
-241,209
| Closed | -$4.92M | – | 12338 |
|
|
2025
Q1 | $4.79M | Buy |
241,209
+82,775
| +52% | +$1.43M | ﹤0.01% | 3950 |
|
|
2024
Q4 | $2.72M | Buy |
+158,434
| New | +$2.98M | ﹤0.01% | 5011 |
|
|
2024
Q3 | – | Sell |
-30,351
| Closed | -$472K | – | 14132 |
|
|
2024
Q2 | $339K | Sell |
30,351
-264,338
| -90% | -$2.22M | ﹤0.01% | 8897 |
|
|
2024
Q1 | $1.94M | Buy |
294,689
+59,931
| +26% | +$328K | ﹤0.01% | 5579 |
|
|
2023
Q4 | $1.06M | Sell |
234,758
-632,585
| -73% | -$2.34M | ﹤0.01% | 6548 |
|
|
2023
Q3 | $3.11M | Buy |
867,343
+812,084
| +1,470% | +$3.13M | ﹤0.01% | 4415 |
|
|
2023
Q2 | $204K | Sell |
55,259
-187,437
| -77% | -$695K | ﹤0.01% | 9853 |
|
|
2023
Q1 | $803K | Buy |
242,696
+90,076
| +59% | +$311K | ﹤0.01% | 7272 |
|
|
2022
Q4 | $592K | Sell |
152,620
-210,137
| -58% | -$648K | ﹤0.01% | 7883 |
|
|
2022
Q3 | $882K | Buy |
362,757
+201,530
| +125% | +$483K | ﹤0.01% | 7259 |
|
|
2022
Q2 | $319K | Sell |
161,227
-76,419
| -32% | -$150K | ﹤0.01% | 9669 |
|
|
2022
Q1 | $435K | Sell |
237,646
-380,603
| -62% | -$594K | ﹤0.01% | 9717 |
|
|
2021
Q4 | $872K | Buy |
618,249
+461,861
| +295% | +$607K | ﹤0.01% | 8286 |
|
|
2021
Q3 | $177K | Buy |
156,388
+28,373
| +22% | +$39.7K | ﹤0.01% | 12150 |
|
|
2021
Q2 | $205K | Sell |
128,015
-92,447
| -42% | -$163K | ﹤0.01% | 12100 |
|
|
2021
Q1 | $388K | Buy |
220,462
+69,683
| +46% | +$159K | ﹤0.01% | 10255 |
|
|
2020
Q4 | $294K | Buy |
+150,779
| New | +$317K | ﹤0.01% | 9111 |
|
|
2020
Q3 | – | Sell |
-145,067
| Closed | -$398K | – | 10002 |
|
|
2020
Q2 | $425K | Buy |
145,067
+106,588
| +277% | +$306K | ﹤0.01% | 7345 |
|
|
2020
Q1 | $111K | Sell |
38,479
-3,428
| -8% | -$11.8K | ﹤0.01% | 8561 |
|
|
2019
Q4 | $168K | Sell |
41,907
-6,904
| -14% | -$30.1K | ﹤0.01% | 8298 |
|
|
2019
Q3 | $217K | Buy |
48,811
+26,624
| +120% | +$111K | ﹤0.01% | 8047 |
|
|
2019
Q2 | $86K | Buy |
+22,187
| New | +$97.9K | ﹤0.01% | 8577 |
|
|
2018
Q2 | – | Sell |
-12,890
| Closed | -$59K | – | 8752 |
|
|
2018
Q1 | $59K | Buy |
+12,890
| New | +$51.2K | ﹤0.01% | 7878 |
|
Other funds holding ADMA
VCM
VPM
N
CP
Ken Griffin's ADMA Position: Q1 2026 in Review
Ken Griffin increased its ADMA Biologics (ADMA) stake by 282% in Q1 2026, buying an estimated $67.7M and bringing the position to 5,810,642 shares worth $52.4M. The position accounts for 0.01% of the portfolio, ranked #1316.
Ken Griffin first reported a position in ADMA in Q1 2018 and has held it in 26 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.
- Ken Griffin held 5,810,642 shares of ADMA Biologics worth $52.4M as of Q1 2026.
- Ken Griffin bought 4,288,072 ADMA Biologics shares in Q1 2026, an estimated $67.7M.
- ADMA Biologics made up 0.01% of Ken Griffin's portfolio in Q1 2026, its #1316 holding.
- Ken Griffin first reported a position in ADMA Biologics in Q1 2018 and has held it in 26 quarters since.
- 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.